विवरण

A rare disease, also referred to as an orphan disease, is any disease that affects a small percentage of the population. There are thousands of rare diseases. To date, six to seven thousand rare diseases have been discovered and new diseases are regularly described in medical literature. The global rare disease diagnostics market in terms of revenue is set to grow by US$ 12 के दौरान अरब 2021-2027, growing at a compound annual growth rate (सीएजीआर) का 8.6% पूर्वानुमान अवधि के दौरान, डेटा और एनालिटिक्स कंपनी स्ट्रैटेजीहेलिक्स के अनुसार. Rising burden of diseases and increase in incidence and prevalence of genetic disorders and various types of cancer, increase in adoption of whole genome and exome sequencing, and increasing research funding and surge in usage for new techniques are driving market growth.

रिपोर्ट अवधि के लिए नवीनतम बाज़ार आकार डेटा प्रदान करती है 2017-2020 और पूर्वानुमान करें 2027 covering key market aspects like sales value for rare disease diagnostics. The global rare disease diagnostics market is segmented on the basis of disease, technology, age, analysis target, और क्षेत्र. By disease, it is categorized into cardiovascular, central nervous system, endocrine and metabolic, hematology, immune and inflammation, rare cancers, and other diseases. The diagnostics for rare cancers segment held the largest market share in 2020. By technology, the rare disease diagnostics market is divided into polymerase chain reaction (PCR), next-generation sequencing, microarrays, और दूसरे. Based on age, the rare disease diagnostics market is divided into children, and adult. Rare disease diagnostics market by analysis target is divided into multiple genes, whole exome, single genes, and whole genome.

The report has profiled some of the key players of the market such as 3billion Inc., Agilent Technologies Inc., BGI Group, Centogene AG, Eurofins Scientific SE, Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, PerkinElmer Inc., Quest Diagnostics Incorporated.

यह रिपोर्ट इस उद्योग में सक्रिय कंपनियों और संगठनों के लिए एक अमूल्य संसाधन है. It provides a cohesive picture of the rare disease diagnostics market to help drive informed decision making for industry executives, नीति निर्माताओं, अकादमिक, और विश्लेषक.

रिपोर्ट का दायरा

Disease: cardiovascular, central nervous system, endocrine and metabolic, hematology, immune and inflammation, rare cancers, and other diseases
Technology: polymerase chain reaction (PCR), next-generation sequencing, microarrays, और दूसरे
Age: children, and adult
क्षेत्र: उत्तरी अमेरिका, एशिया प्रशांत, यूरोप, and Rest of the World (ROW)
Analysis target: multiple genes, whole exome, single genes, and whole genome
वर्षों पर विचार किया गया: यह रिपोर्ट उस अवधि को कवर करती है 2017 को 2027

हितधारकों के लिए मुख्य लाभ

Get a comprehensive picture of the global rare disease diagnostics market
Identify regional strategies and strategic priorities on the basis of local data and analysis
विकास क्षेत्रों और निवेश के रुझानों को इंगित करें
Understand what the future of the global rare disease diagnostics market looks like
प्रतिस्पर्धी परिदृश्य और अवसर की खिड़की की पहचान करें

विषयसूची

1. बाज़ार परिभाषा
2. अनुसंधान क्रियाविधि
3. बाजार के आंकड़े & आउटलुक
3.1 बाजार मूल्य
3.2 बाज़ार मूल्य का पूर्वानुमान
4. Rare Disease Diagnostics Market by Disease
4.1 Cardiovascular
4.2 Central Nervous System
4.3 Endocrine And Metabolic
4.4 Hematology
4.5 Immune And Inflammation
4.6 Rare Cancers
4.7 Other Diseases
5. Rare Disease Diagnostics Market by Technology
5.1 Polymerase Chain Reaction (Pcr)
5.2 Next-Generation Sequencing
5.3 Microarrays
5.4 अन्य
6. Rare Disease Diagnostics Market by Age
6.1 Children
6.2 Adult
7. Rare Disease Diagnostics Market by Analysis Target
7.1 Multiple Genes
7.2 Whole Exome
7.3 Single Genes
7.4 Whole Genome
8. Rare Disease Diagnostics Market by Region
8.1 उत्तरी अमेरिका
8.2 एशिया प्रशांत
8.3 यूरोप
8.4 Rest Of The World (Row)
9. कंपनी प्रोफाइल
9.1 3billion Inc.
9.2 Agilent Technologies Inc.
9.3 BGI Group
9.4 Centogene AG
9.5 Eurofins Scientific SE
9.6 Illumina Inc.
9.7 Invitae Corporation
9.8 Laboratory Corporation of America Holdings
9.9 PerkinElmer, इंक.
9.10 Quest Diagnostics Incorporated
10. अनुबंध
10.1 स्ट्रेटेजीहेलिक्स के बारे में
10.2 अस्वीकरण